☆ 4.2 Article

Update from the 2013 International Neurofibromatosis Conference

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2014)

Journal

AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Volume 164, Issue 12, Pages 2969-2978

Publisher

WILEY

DOI: 10.1002/ajmg.a.36754

Keywords

NF1; NF2; SMARCB1; neurofibromatosis 1; neurofibromatosis 2; schwannomatosis; tumor suppressor; merlin; neurofibromin; preclinical models

Categories

Genetics & Heredity

Funding

National Institutes of Health [1R13NS084619-01]
MRC [MR/J012785/1] Funding Source: UKRI
Cancer Research UK [11244, 17135] Funding Source: researchfish
Medical Research Council [MR/J012785/1] Funding Source: researchfish
Worldwide Cancer Research [12-0041] Funding Source: researchfish

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Genetics & Heredity

Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

Scott R. Plotkin, Ludwine Messiaen, Eric Legius, Patrice Pancza, Robert A. Avery, Jaishri O. Blakeley, Dusica Babovic-Vuksanovic, Rosalie Ferner, Michael J. Fisher, Jan M. Friedman, Marco Giovannini, David H. Gutmann, Clemens Oliver Hanemann, Michel Kalamarides, Hildegard Kehrer-Sawatzki, Bruce R. Korf, Victor-Felix Mautner, Mia MacCollin, Laura Papi, Katherine A. Rauen, Vincent Riccardi, Elizabeth Schorry, Miriam J. Smith, Anat Stemmer-Rachamimov, David A. Stevenson, Nicole J. Ullrich, David Viskochil, Katharina Wimmer, Kaleb Yohay, Susan M. Huson, Pierre Wolkenstein, D. Gareth Evans

Summary: The study aims to update the diagnostic criteria for neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) by incorporating recent advances in genetics, ophthalmology, neuropathology, and neuroimaging. The updated criteria include clinical features and genetic testing, emphasizing the phenotypic overlap between the two conditions.

GENETICS IN MEDICINE (2022)

Add to Collection

Review Clinical Neurology

Diagnostic Pathology of Tumors of Peripheral Nerve

Sarra M. Belakhoua, Fausto J. Rodriguez

Summary: This review discusses the classification, diagnosis, and pathological features of peripheral nerve sheath tumors, covering a range from benign to highly malignant tumors, and also discusses the association of these tumors with specific genetic and familial syndromes. In addition, updates in molecular biology research in this field are also introduced.

NEUROSURGERY (2021)

Add to Collection

Review Oncology

MEK inhibitors-novel targeted therapies of neurofibromatosis associated benign and malignant lesions

Anja Harder

Summary: MEK 1/2 inhibitors (MEKi) have shown potential in reducing the volume of low grade gliomas and plexiform neurofibromas in NF1, and research targeting other high morbidity lesions in NF1 also shows promise. Moreover, MEKi are used in combination therapies due to involvement of multiple pathways in NF2 associated lesions and malignant tumors.

BIOMARKER RESEARCH (2021)

Add to Collection

Article Genetics & Heredity

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis

Jineta Banerjee, Jan M. Friedman, Laura J. Klesse, Kaleb H. Yohay, Justin T. Jordan, Scott R. Plotkin, Robert J. Allaway, Jaishri O. Blakeley

Summary: This study investigated whether patients with rare diseases such as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), or schwannomatosis (SWN) are more susceptible to SARS-CoV-2 infection and severe COVID-19. The results showed that the proportion of positive cases in NF1, NF2, or SWN patients was not significantly higher than in individuals without these rare diseases. There were no severe outcomes reported in the NF2 or SWN cohorts, and the proportion of severe outcomes in NF1 patients was similar to other rare disease cohorts and the general population.

GENETICS IN MEDICINE (2023)

Add to Collection

Article Multidisciplinary Sciences

Gatekeeping role of Nf2/Merlin in vascular tip EC induction through suppression of VEGFR2 internalization

Jung Hyun Bae, Myung Jin Yang, Seung-Hwan Jeong, JungMo Kim, Seon Pyo Hong, Jin Woo Kim, Yoo Hyung Kim, Gou Young Koh

Summary: In this study, the researchers discovered that Merlin, encoded by the neurofibromatosis type 2 (NF2) gene, suppresses VEGFR2 internalization and controls the induction of tip endothelial cells (EC). Depletion of Nf2 in endothelial cells enhances VEGFR2 internalization and leads to excessive filopodia formation in tip EC induction. Merlin binds to the VEGFR2-VE-cadherin complex and reduces downstream signaling, thus affecting the induction of tip ECs.

SCIENCE ADVANCES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The Contribution of Oxidative Stress to NF1-Altered Tumors

Elisabetta Kuhn, Federica Natacci, Massimo Corbo, Luigi Pisani, Stefano Ferrero, Gaetano Bulfamante, Donatella Gambini

Summary: The NF1 gene is a tumor suppressor gene that controls tumor development through several molecular mechanisms. It is frequently mutated in human cancer, with mutations occurring in approximately 5-10% of all tumors. Loss of neurofibromin, the protein encoded by NF1, leads to hyperactivation of tumor-related signaling pathways and promotes cell mobility, proliferation, chromosomal instability, and aneuploidy. Oxidative stress plays a key role in NF1-related tumorigenesis.

ANTIOXIDANTS (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas

Maximilian Scheer, Sandra Leisz, Eberhard Sorge, Olha Storozhuk, Julian Prell, Ivy Ho, Anja Harder

Summary: NF1 gene mutations are found in various tumors, and loss of NF1 function plays a crucial role in inducing the aggressive MES subtype in glioblastoma. This process is mediated through the NF1-MAPK-FOSL1 axis and may offer novel therapeutic targets.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis

D. Gareth Evans, Stefania Mostaccioli, David Pang, Mary Fadzil O. Connor, Melpo Pittara, Nicolas Champollion, Pierre Wolkenstein, Nick Thomas, Rosalie E. Ferner, Michel Kalamarides, Matthieu Peyre, Laura Papi, Eric Legius, Juan Luis Becerra, Andrew King, Chris Duff, Stavros Stivaros, Ignacio Blanco

Summary: This article presents the development of the first comprehensive guideline for schwannomatosis by a guideline group composed of multiple specialties and patients. The group conducted a thorough literature review and provided recommendations for treatment and surveillance. The article also discusses the genetic basis of schwannomatosis and describes common diagnostic methods and treatment options.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Add to Collection

Article Oncology

TnIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin

Pedro Torres-Ayuso, Elvira An, Katherine M. Nyswaner, Ryan C. Bensen, Daniel A. Ritt, Suzanne Specht, Sudipto Das, Thorkell Andresson, Raul E. Cachau, Roger J. Liang, Amy L. Ries, Christina M. Robinson, Simone Difilippantonio, Brad Gouker, Laura Bassel, Baktiar O. Karim, Chad J. Miller, Benjamin E. Turk, Deborah K. Morrison, John Brognard

Summary: Research identified TNIK as a potential therapeutic target in LSCC, with genetic depletion or pharmacologic inhibition showing efficacy in reducing the growth of LSCC cells. In preclinical models, TNIK inhibition displayed antitumor activity and increased apoptosis in LSCC patient-derived xenografts.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma

Scott R. Plotkin, Jeffrey Allen, Girish Dhall, Jian L. Campian, D. Wade Clapp, Michael J. Fisher, Rakesh K. Jain, James Tonsgard, Nicole J. Ullrich, Coretta Thomas, Lloyd J. Edwards, Bruce Korf, Roger Packer, Matthias A. Karajannis, Jaishri O. Blakeley

Summary: In this prospective multicenter phase II study, the efficacy, safety, and tolerability of bevacizumab for maintenance therapy in persons with NF2-SWN and hearing loss due to VS were evaluated. The results showed that maintenance bevacizumab (5 mg/kg every 3 weeks) was associated with high rates of hearing and tumor stability during 18 months of follow-up. No new unexpected adverse events related to bevacizumab were identified in this population.

NEURO-ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor

Gun-Hoo Park, Su-Jin Lee, Chang-Gun Lee, Jeonghyun Kim, Eunkuk Park, Seon-Yong Jeong

Summary: In NF1-associated MPNSTs, EGFR expression is upregulated while neurofibromin expression is decreased. Deficiency of neurofibromin may enhance the Ras/ERK/SP1 signaling pathway leading to the upregulation of EGFR expression.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Multidisciplinary Sciences

Cell-cell adhesion regulates Merlin/NF2 interaction with the PAF complex

Anne E. Roehrig, Kristina Klupsch, Juan A. Oses-Prieto, Selim Chaib, Stephen Henderson, Warren Emmett, Lucy C. Young, Silvia Surinova, Andreas Blees, Anett Pfeiffer, Maha Tijani, Fabian Brunk, Nicole Hartig, Marta Munoz-Alegre, Alexander Hergovich, Barbara H. Jennings, Alma L. Burlingame, Pablo Rodriguez-Viciana

Summary: The study investigates the roles of the PAF complex and Merlin tumor suppressor protein in RNA processing, highlighting their interaction for growth suppression. Additionally, the involvement of FAT cadherins in regulating Merlin-PAFC interaction is identified as a significant finding from the research.

PLOS ONE (2021)

Add to Collection

Article Medicine, Research & Experimental

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2

Shilpa Prabhakar, Roberta L. Beauchamp, Pike See Cheah, Akiko Yoshinaga, Edwina Abou Haidar, Sevda Lule, Gayathri Mani, Katia Maalouf, Anat Stemmer-Rachamimov, David H. Jung, Bradley Welling, Marco Giovannini, Scott R. Plotkin, Casey A. Maguire, Vijaya Ramesh, Xandra O. Breakefield

Summary: Loss of function of the NF2 tumor suppressor gene leads to the formation of certain types of tumors. This study demonstrates that introducing merlin back into NF2-null schwannomas through gene replacement can cause tumor regression. In a mouse model, injection of AAV1-merlin resulted in decreased tumor size, reduced cell division, and increased apoptosis.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Add to Collection

Review Clinical Neurology

What to know about schwannomatosis: a literature review

Cedric Schraepen, Peter Donkersloot, Wim Duyvendak, Mark Plazier, Eric Put, Gert Roosen, Steven Vanvolsem, Maarten Wissels, Sven Bamps

Summary: Schwannomatosis is a relatively rare disorder related to neurofibromatosis type 2. The main symptom is pain affecting the spine and peripheral nerves. Diagnosis relies on genetic testing and MRI scans. Treatment options include conservative management and surgery.

BRITISH JOURNAL OF NEUROSURGERY (2022)

Add to Collection

Review Genetics & Heredity

Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk

Jillian L. Chen, David T. Miller, Laura S. Schmidt, David Malkin, Bruce R. Korf, Charis Eng, David J. Kwiatkowski, Krinio Giannikou

Summary: This review examines the current state of mosaic individuals with eight common tumor suppressor genes, discussing diagnostic genetic testing, variant allele frequency, and disease severity. It also explores affected individuals without identified mutations, genotype-phenotype correlations, and transmission risk in heterozygous and mosaic patients.

ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS (2022)

Add to Collection

Article Genetics & Heredity

The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2

Sue Philpott, Maria Raikou, Ranjit Manchanda, Michelle Lockley, Naveena Singh, Malcolm Scott, D. Gareth Evans, Julian Adlard, Munaza Ahmed, Richard Edmondson, Emma Roisin Woodward, Athena Lamnisos, Janos Balega, Angela F. Brady, Aarti Sharma, Louise Izatt, Anjana Kulkarni, Vishakha Tripathi, Joyce S. Solomons, Kevin Hayes, Helen Hanson, Katie Snape, Lucy Side, Steve Skates, Alistair McGuire, Adam N. Rosenthal

Summary: This study aimed to evaluate the effectiveness and cost-effectiveness of ovarian cancer surveillance in BRCA1/2-heterozygous women deferring risk-reducing surgery. The results showed that surveillance in a real-world setting was feasible and demonstrated similar performance to research trials, effectively down-staging ovarian cancer and saving costs.

JOURNAL OF MEDICAL GENETICS (2023)

Add to Collection

Article Endocrinology & Metabolism

Child and adult adiposity and subtype-specific endometrial cancer risk: a multivariable Mendelian randomisation study

Oliver J. Kennedy, Cemsel Bafligil, Tracy A. O'Mara, Xuemin Wang, D. Gareth Evans, Siddhartha Kar, Emma J. Crosbie

Summary: Adult adiposity is a significant risk factor for overall and endometrioid endometrial cancer risk. Child adiposity has minimal effect on overall risk but increases non-endometrioid endometrial cancer risk. These findings highlight the importance of interventions targeting adiposity at different life stages in preventing subtype-specific endometrial cancer.

INTERNATIONAL JOURNAL OF OBESITY (2023)

Add to Collection

Article Genetics & Heredity

UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2

Helen Hanson, Anjana Kulkarni, Lucy Loong, Grace Kavanaugh, Bethany Torr, Sophie Allen, Munaza Ahmed, Antonis C. Antoniou, Ruth Cleaver, Tabib Dabir, D. Gareth Evans, Ellen Golightly, Rosalyn Jewell, Kelly Kohut, Ranjit Manchanda, Alex Murray, Jennie Murray, Kai-Ren Ong, Adam N. Rosenthal, Emma Roisin Woodward, Diana M. Eccles, Clare Turnbull, Marc Tischkowitz, Fiona Lalloo

Summary: This paper presents a summary of the process and key recommendations from a national consensus on the clinical management of BRIP1, PALB2, RAD51D, and RAD51C carriers.

JOURNAL OF MEDICAL GENETICS (2023)

Add to Collection

Article Genetics & Heredity

Differential rates of germline heterozygote and mosaic variants in NF2 may show varying propensity for meiotic or mitotic mutation

D. Gareth Evans, George J. Burghel, Miriam Jane Smith

Summary: NF2-related schwannomatosis is a genetic condition that causes multiple benign tumors of the nervous system. It is caused by pathogenic variants in the NF2 gene, with six specific CpG nonsense variants being responsible for a majority of the cases. The de novo heterozygote to mosaicism ratio of one of these variants, NF2 c.586C>T; p.(Arg196Ter), is higher compared to the others, possibly due to variations in mutation rates during meiosis and mitosis.

JOURNAL OF MEDICAL GENETICS (2023)

Add to Collection

Article Oncology

Perspectives on the implications of carrying putative pathogenic variants in the medulloblastoma predisposition genes ELP1 and GPR161

Miriam J. Smith, Emma R. Woodward, D. Gareth Evans

Summary: Recent genetic sequencing studies have identified loss-of-function variants in the ELP1 and GPR161 genes as causes of childhood medulloblastoma. Although there is speculation that GPR161 may also cause Gorlin syndrome, the projected risks of developing medulloblastoma with these gene variants are relatively low and do not warrant MRI screening in infants.

FAMILIAL CANCER (2023)

Add to Collection

Article Genetics & Heredity

Optimization of polygenic risk scores in BRCA1/2 pathogenic variant heterozygotes in epithelial ovarian cancer

Nicola Flaum, John Bowes, Miriam J. Smith, Emma J. Crosbie, Richard Edmondson, Artitaya Lophatananon, D. Gareth Evans

Summary: This study evaluated the association between BRCA1/2 heterozygotes and familial epithelial ovarian cancer (EOC) by constructing modified polygenic risk scores (PRS) validated by Barnes et al. It was found that combining PRS with age, family history, and hormonal factors significantly improved the discrimination ability of EOC risk, although the contribution of PRS was small. Larger prospective studies are needed to assess the usefulness of combined-PRS models in risk-reducing decisions.

GENETICS IN MEDICINE (2023)

Add to Collection

Article Neurosciences

A Targeted, Low-Throughput Compound Screen in a Drosophila Model of Neurofibromatosis Type 1 Identifies Simvastatin and BMS-204352 as Potential Therapies for Autism Spectrum Disorder (ASD)

Alex Dyson, Megan Ryan, Shruti Garg, Gareth Evans, Richard A. Baines

Summary: Autism spectrum disorder (ASD) is a neurodevelopmental condition with no effective pharmacological therapies. In a study using Drosophila larvae, it was found that compounds like simvastatin and BMS-204352 could reduce tactile hypersensitivity, a symptom of ASD, but not fully rescue it.

ENEURO (2023)

Add to Collection

Correction Health Care Sciences & Services

Evaluating the Acceptance and Usability of an App Promoting Weight Gain Prevention and Healthy Behaviors Among Young Women With a Family History of Breast Cancer: Protocol for an Observational Study ( vol 12, e47765 , 2022 )

Mary Pegington, Alan Davies, Julia Mueller, Rachel Cholerton, Anthony Howell, D. Gareth Evans, Sacha J. Howell, David P. French, Michelle Harvie

JMIR RESEARCH PROTOCOLS (2023)

Add to Collection

Article Health Policy & Services

The role of knowledge, primary care and community engagement to improve breast-screening access for Pakistani women in the United Kingdom: A secondary analysis of a qualitative study

Hooran M. Khattak, Victoria G. Woof, David P. French, Louise S. Donnelly, Helen Ruane, Fiona Ulph, Nadeem Qureshi, Nasaim Khan, D. Gareth Evans, Kathryn A. Robb

Summary: The objective of this study was to improve access to breast screening for British-Pakistani women by understanding their knowledge of breast cancer and the role of primary care and community networks. The findings suggested the need for co-produced strategies, collaboration with General Practitioners, and community engagement to increase knowledge and support informed choices about screening.

JOURNAL OF HEALTH SERVICES RESEARCH & POLICY (2023)

Add to Collection

Article Medicine, General & Internal

Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database

Mev Dominguez-Valentin, Saskia Haupt, Toni T. Seppaelae, Julian R. Sampson, Lone Sunde, Inge Bernstein, Mark A. Jenkins, Christoph Engel, Stefan Aretz, Maartje Nielsen, Gabriel Capella, Francesc Balaguer, Dafydd Gareth Evans, John Burn, Elke Holinski-Feder, Lucio Bertario, Bernardo Bonanni, Annika Lindblom, Zohar Levi, Finlay Macrae, Ingrid Winship, John-Paul Plazzer, Rolf Sijmons, Luigi Laghi, Adriana Della Valle, Karl Heinimann, Tadeusz Debniak, Robert Fruscio, Francisco Lopez-Koestner, Karin Alvarez-Valenzuela, Lor H. Katz, Ido Laish, Elez Vainer, Carlos Vaccaro, Dirce Maria Carraro, Kevin Monahan, Elizabeth Half, Aine Stakelum, Des Winter, Rory Kennelly, Nathan Gluck, Harsh Sheth, Naim Abu-Freha, Marc Greenblatt, Benedito Mauro Rossi, Mabel Bohorquez, Giulia Martina Cavestro, Leonardo S. Lino-Silva, Karoline Horisberger, Maria Grazia Tibiletti, Ivana do Nascimento, Huw Thomas, Norma Teresa Rossi, Leandro Apolinario da Silva, Attila Zarand, Juan Ruiz-Banobre, Vincent Heuveline, Jukka-Pekka Mecklin, Kirsi Pylvaenaeinen, Laura Renkonen-Sinisalo, Anna Lepistoe, Paeivi Peltomaeki, Christina Therkildsen, Mia Gebauer Madsen, Stefan Kobbelgaard Burgdorf, John L. Hopper, Aung Ko Win, Robert W. Haile, Noralane Lindor, Steven Gallinge, Loic Le Marchand, Polly A. Newcomb, Jane Figueiredo, Daniel D. Buchanan, Stephen N. Thibodeau, Magnus von Knebel Doeberitz, Markus Loeffler, Nils Rahner, Evelin Schroeck, Verena Steinke-Lange, Wolff Schmiegel, Deepak Vangala, Claudia Perne, Robert Hueneburg, Silke Redler, Reinhard Buettner, Jurgen Weitz, Marta Pineda, Nuria Duenas, Joan Brunet Vidal, Leticia Moreira, Ariadna Sanchez, Eivind Hovig, Sigve Nakken, Kate Green, Fiona Lalloo, James Hill, Emma Crosbie, Miriam Mints, Yael Goldberg, Douglas Tjandra, Sanne W. ten Broeke, Revital Kariv, Guy Rosner, Suresh H. Advani, Lidiya Thomas, Pankaj Shah, Mithun Shah, Florencia Neffa, Patricia Esperon, Walter Pavicic, Giovana Tardin Torrezan, Thiago Bassaneze, Claudia Alejandra Martin, Gabriela Moslein, Pal Moller

Summary: This study used the latest PLSD cohort to investigate the mortality rates and age of cancer diagnoses in carriers of pathogenic MMR variants. The results showed that non-colorectal Lynch syndrome cancers caused more deaths than colorectal cancers in these carriers. Reducing deaths from non-colorectal cancers is a crucial challenge for the medical care of Lynch syndrome.

ECLINICALMEDICINE (2023)

Add to Collection

Article Oncology

The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis

Grace E. Gregory, Abdurrahman I. Islim, Cathal John Hannan, Adam P. Jones, Charlotte Hammerbeck-Ward, Scott A. Rutherford, Simon R. Freeman, Simon Lloyd, Michel Kalamarides, Miriam J. Smith, Kevin Couper, Catherine A. McBain, Michael D. Jenkinson, David Brough, Andrew T. King, D. Gareth Evans, Omar N. Pathmanaban

Summary: NF2-schwannomatosis is a genetic syndrome associated with meningioma. Meningioma in NF2-schwannomatosis is a major cause of morbidity and mortality. The management of meningioma in NF2-schwannomatosis differs from sporadic tumors, with a focus on conservative management and surgical intervention if necessary.

NEURO-ONCOLOGY ADVANCES (2023)

Add to Collection

Article Genetics & Heredity

Validation of lung cancer polygenic risk scores in a high-risk case-control cohort

Mikey B. Lebrett, Miriam J. Smith, Emma J. Crosbie, John Bowes, Helen J. Byers, Gareth Evans, Philip A. J. Crosbie

Summary: The study investigated the performance of previously published polygenic risk scores (PRSs) for lung cancer (LC) and found that genetic variables could be used for screening selection and potentially improve screening effectiveness. Among the 9 PRSs validated in a high-risk case-control cohort, the best-performing PRS had an independent high area under the curve (AUC). Two novel loci, in the DAPK1 and MAGI2 genes, were significantly associated with LC risk. These findings suggest that PRSs may improve LC risk prediction and screening selection.

GENETICS IN MEDICINE (2023)

Add to Collection

Article Oncology

A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry

Pooja K. Middha, Xiaoliang Wang, Sabine Behrens, Manjeet K. Bolla, Qin Wang, Joe Dennis, Kyriaki Michailidou, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Kristan J. Aronson, Paul L. Auer, Annelie Augustinsson, Thais Baert, Laura E. Beane Freeman, Heiko Becher, Matthias W. Beckmann, Javier Benitez, Stig E. Bojesen, Hiltrud Brauch, Hermann Brenner, Angela Brooks-Wilson, Daniele Campa, Federico Canzian, Angel Carracedo, Jose E. Castelao, Stephen J. Chanock, Georgia Chenevix-Trench, Emilie Cordina-Duverger, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Laure Dossus, Pierre-Antoine Dugue, A. Heather Eliassen, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Jonine Figueroa, Olivia Fletcher, Henrik Flyger, Marike Gabrielson, Manuela Gago-Dominguez, Graham G. Giles, Anna Gonzalez-Neira, Felix Grassmann, Anne Grundy, Pascal Guenel, Christopher A. Haiman, Niclas Hakansson, Per Hall, Ute Hamann, Susan E. Hankinson, Elaine F. Harkness, Bernd Holleczek, Reiner Hoppe, John L. Hopper, Richard S. Houlston, Anthony Howell, David J. Hunter, Christian Ingvar, Karolin Isaksson, Helena Jernstroem, Esther M. John, Michael E. Jones, Rudolf Kaaks, Renske Keeman, Cari M. Kitahara, Yon-Dschun Ko, Stella Koutros, Allison W. Kurian, James V. Lacey, Diether Lambrechts, Nicole L. Larson, Susanna Larsson, Loic Le Marchand, Flavio Lejbkowicz, Shuai Li, Martha Linet, Jolanta Lissowska, Maria Elena Martinez, Tabea Maurer, Anna Marie Mulligan, Claire Mulot, Rachel A. Murphy, William G. Newman, Sune F. Nielsen, Borge G. Nordestgaard, Aaron Norman, Katie M. O'Brien, Janet E. Olson, Alpa V. Patel, Ross Prentice, Erika Rees-Punia, Gad Rennert, Valerie Rhenius, Kathryn J. Ruddy, Dale P. Sandler, Christopher G. Scott, Mitul T. Shah, Xiao-Ou Shu, Ann Smeets, Melissa C. Southey, Jennifer Stone, Rulla M. Tamimi, Jack A. Taylor, Lauren R. Teras, Katarzyna Tomczyk, Melissa A. Troester, Therese Truong, Celine M. Vachon, Sophia S. Wang, Clarice R. Weinberg, Hans Wildiers, Walter Willett, Stacey J. Winham, Alicja Wolk, Xiaohong Yang, M. Pilar Zamora, Wei Zheng, Argyrios Ziogas, Alison M. Dunning, Paul D. P. Pharoah, Montserrat Garcia-Closas, Marjanka K. Schmidt, Peter Kraft, Roger L. Milne, Sara Lindstroem, Douglas F. Easton, Jenny Chang-Claude

Summary: A genome-wide study identified two independent SNP-risk factor pairs associated with breast cancer risk and estrogen receptor positive (ER +) breast cancer risk. Overall, gene-environment interactions have a very small contribution to the heritability of breast cancer. At the population level, these interactions do not significantly contribute to risk prediction for breast cancer.

BREAST CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Impact of time between last childbirth and diagnosis of early-onset breast cancer on survival in germline BRCA1/2 carriers

Zhenzhen Zhang, Shangyuan Ye, D. Gareth Evans, Pepper Schedin

CANCER RESEARCH (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.